RDE Treatment Prevents Non-Specific Detection of SARS-CoV-2- and Influenza-Specific IgG Antibodies in Heat-Inactivated Serum Samples.

ELISA SARS-CoV-2 heat inactivation influenza receptor-destroying enzyme serum antibody

Journal

Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489

Informations de publication

Date de publication:
16 Jun 2023
Historique:
received: 01 05 2023
revised: 28 05 2023
accepted: 12 06 2023
medline: 27 6 2023
pubmed: 27 6 2023
entrez: 27 6 2023
Statut: epublish

Résumé

Assessing the levels of serum IgG antibodies is widely used to measure immunity to influenza and the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after natural infection or vaccination with specific vaccines, as well as to study immune responses to these viruses in animal models. For safety reasons, sometimes serum specimens collected from infected individuals are subjected to heat inactivation at 56 °C to reduce the risk of infecting personnel during serological studies. However, this procedure may affect the level of virus-specific antibodies, making the results of antibody immunoassays uninterpretable. Here, we evaluated the effect of the heat inactivation of human, ferret and hamster serum samples on the binding of IgG antibodies to the influenza and SARS-CoV-2 antigens. For this, serum samples of naive and immune hosts were analyzed in three variants: (i) untreated sera, (ii) heated at 56 °C for 1 h, and (iii) treated with receptor-destroying enzyme (RDE). The samples were studied through an in-house enzyme-linked immunosorbent assay (ELISA) using whole influenza virus or recombinant proteins corresponding to nucleocapsid (N) protein and the receptor-binding domain of SARS-CoV-2 Spike (RBD) as antigens. We demonstrated that the heat inactivation of the naive serum samples of various hosts can lead to false-positive results, while RDE treatment abolished the effect of the non-specific binding of IgG antibodies to the viral antigens. Furthermore, RDE also significantly decreased the level of virus-specific IgG antibodies in SARS-CoV-2 and influenza-immune sera of humans and animals, although it is unknown whether it actually removes true virus-specific IgG antibodies or only non-specifically binding artifacts. Nevertheless, we suggest that the RDE treatment of human and animal sera may be useful in preventing false-positive results in various immunoassays, while also neutralizing infectious virus, since the standard protocol for the use of RDE also includes heating the sample at 56 °C.

Identifiants

pubmed: 37366655
pii: antib12020039
doi: 10.3390/antib12020039
pmc: PMC10295076
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Russian Science Foundation
ID : 21-75-30003

Références

Sci Transl Med. 2013 Aug 28;5(200):200ra114
pubmed: 23986398
Immunol Rev. 2022 Sep;310(1):27-46
pubmed: 35733376
J Clin Microbiol. 1986 Feb;23(2):381-2
pubmed: 3009536
Biochem Biophys Res Commun. 2021 Jan 29;538:187-191
pubmed: 33187644
Expert Rev Vaccines. 2016 Sep;15(9):1123-34
pubmed: 26985862
Sci Rep. 2022 Apr 5;12(1):5680
pubmed: 35383204
J Integr Bioinform. 2021 Mar 25;18(1):27-43
pubmed: 33761582
Expert Rev Clin Immunol. 2021 Jun;17(6):573-599
pubmed: 33787412
Immunology. 1979 Jan;36(1):37-45
pubmed: 422227
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Science. 2022 Mar 11;375(6585):1127-1132
pubmed: 35271316
Lancet Respir Med. 2021 Apr;9(4):333-335
pubmed: 33524316
J Proteome Res. 2020 Nov 6;19(11):4428-4441
pubmed: 32852212
Biol Pharm Bull. 1996 Jan;19(1):132-5
pubmed: 8820925
Vaccines (Basel). 2018 Nov 01;6(4):
pubmed: 30388790
Vaccines (Basel). 2022 Jul 18;10(7):
pubmed: 35891306
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Biosaf Health. 2022 Aug;4(4):228-233
pubmed: 35856045
Mil Med Res. 2021 Aug 31;8(1):47
pubmed: 34465396
Biochem Biophys Res Commun. 2014 Aug 22;451(2):208-14
pubmed: 25073113
Clin Chim Acta. 2020 Oct;509:288-292
pubmed: 32569631
Hum Vaccin Immunother. 2015;11(12):2839-48
pubmed: 26697973
Lab Anim (NY). 2004 Oct;33(9):50-3
pubmed: 15457202
J Virol Methods. 2021 Apr;290:114064
pubmed: 33453299
J Virol. 2018 Jan 30;92(4):
pubmed: 29212926
Viruses. 2022 May 18;14(5):
pubmed: 35632823
Mol Biol Rep. 2022 Jun;49(6):4943-4957
pubmed: 35235159
Front Microbiol. 2021 Aug 31;12:626553
pubmed: 34531831
PLoS One. 2012;7(9):e45851
pubmed: 23049879
Sci Rep. 2017 Sep 29;7(1):12471
pubmed: 28963503
Front Microbiol. 2022 Aug 08;13:876227
pubmed: 36003928
Pathogens. 2021 Jan 30;10(2):
pubmed: 33573221
Front Mol Biosci. 2021 Jul 23;8:682405
pubmed: 34368226
Vaccine. 2015 Sep 22;33(39):5110-7
pubmed: 26296497
Influenza Other Respir Viruses. 2012 Mar;6(2):127-35
pubmed: 21883963
Viruses. 2021 Jun 30;13(7):
pubmed: 34209093
Viruses. 2020 Jul 07;12(7):
pubmed: 32646015
Viruses. 2021 Jul 29;13(8):
pubmed: 34452355
Future Virol. 2021 Nov;:
pubmed: 34950219
J Virol. 1991 Jan;65(1):389-95
pubmed: 1702161
Viruses. 2022 Sep 14;14(9):
pubmed: 36146847
Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15194-15199
pubmed: 31296560
Vaccine. 2017 Jan 3;35(1):46-52
pubmed: 27899226
Viruses. 2021 Jan 15;13(1):
pubmed: 33467732
Clin Diagn Lab Immunol. 2005 Aug;12(8):959-69
pubmed: 16085914
J Clin Lab Anal. 2020 Sep;34(9):e23411
pubmed: 32594577
Int J Environ Res Public Health. 2022 Sep 29;19(19):
pubmed: 36231717
Emerg Microbes Infect. 2022 Dec;11(1):2383-2392
pubmed: 36069511
Nat Rev Immunol. 2020 Jul;20(7):392-394
pubmed: 32514035
J Intern Med. 2022 Jan;291(1):32-50
pubmed: 34352148

Auteurs

Arina Goshina (A)

Department of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.

Victoria Matyushenko (V)

Department of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.

Daria Mezhenskaya (D)

Department of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.

Alexandra Rak (A)

Department of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.

Anastasia Katelnikova (A)

Department of Toxicology and Microbiology, Institute of Preclinical Research Ltd., 188663 Saint Petersburg, Russia.

Denis Gusev (D)

Botkin Infectious Diseases Hospital, Piskarovskiy Ave 49, 195067 Saint Petersburg, Russia.

Larisa Rudenko (L)

Department of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.

Irina Isakova-Sivak (I)

Department of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.

Classifications MeSH